OKYO Retained Earnings from 2010 to 2024

OKYO Stock  USD 1.04  0.03  2.97%   
OKYO Pharma Retained Earnings yearly trend continues to be very stable with very little volatility. Retained Earnings are likely to grow to about -135.4 M this year. Retained Earnings is the cumulative amount of net income that OKYO Pharma Ltd retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2008-03-31
Previous Quarter
-125.7 M
Current Value
-125.7 M
Quarterly Volatility
40.1 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check OKYO Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OKYO Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 K, Interest Expense of 1.1 M or Selling And Marketing Expenses of 1.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0254 or Days Sales Outstanding of 0.0. OKYO financial statements analysis is a perfect complement when working with OKYO Pharma Valuation or Volatility modules.
  
Check out the analysis of OKYO Pharma Correlation against competitors.

Latest OKYO Pharma's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of OKYO Pharma Ltd over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. OKYO Pharma's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OKYO Pharma's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (142.52 M)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

OKYO Retained Earnings Regression Statistics

Arithmetic Mean(79,606,586)
Coefficient Of Variation(49.65)
Mean Deviation31,952,643
Median(66,004,637)
Standard Deviation39,520,724
Sample Variance1561.9T
Range139.5M
R-Value(0.96)
Mean Square Error134T
R-Squared0.92
Slope(8,477,869)
Total Sum of Squares21866.4T

OKYO Retained Earnings History

2024-135.4 M
2023-142.5 M
2022-125.7 M
2021-112.4 M
2020-106 M
2019-85.9 M
2018-89 M

About OKYO Pharma Financial Statements

OKYO Pharma investors utilize fundamental indicators, such as Retained Earnings, to predict how OKYO Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Retained Earnings-142.5 M-135.4 M

Pair Trading with OKYO Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OKYO Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OKYO Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against OKYO Stock

  0.58CTLT CatalentPairCorr
  0.48AKAN Akanda CorpPairCorr
  0.4MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.38CVS CVS Health CorpPairCorr
  0.38SBM Sirona Biochem CorpPairCorr
The ability to find closely correlated positions to OKYO Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OKYO Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OKYO Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OKYO Pharma Ltd to buy it.
The correlation of OKYO Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OKYO Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OKYO Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OKYO Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether OKYO Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OKYO Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Okyo Pharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Okyo Pharma Ltd Stock:
Check out the analysis of OKYO Pharma Correlation against competitors.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.57)
Return On Assets
(2.92)
Return On Equity
(29.69)
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.